Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?

Hims & Hers shares have fallen 15.6% over three months despite reporting strong Q3 2025 top-line growth and subscriber gains, as margin contraction and weak bottom-line results drove investor concern; management guided Q4 revenue of $605–625 million (up 26–30% YoY) and FY revenue of $2.335–2.355 billion (up ~58–59% YoY) while consensus EPS sits at $0.04 for Q4 and $0.48 for the year. The company faces material execution and regulatory risks as it expands into sterile compounding, peptide manufacturing and lab testing, and uncertainty over compounded GLP‑1 therapies could disrupt a key weight‑loss revenue stream, while rapid scaling and intensifying competition threaten customer economics and brand trust. Offsetting these risks are strategic initiatives — the Labs testing platform, category expansion into menopause and hormone care, the ZAVA acquisition and international rollout (including Canada), plus AI investments — and a forward P/S of 2.9x below the industry average, though Zacks currently ranks the stock a #4 (Sell) pending clearer evidence of margin and regulatory control.

Analysis

Hims & Hers (HIMS) has fallen 15.6% over the past three months despite reporting robust Q3 2025 top-line strength and subscriber growth; management guided Q4 revenue of $605–$625 million (up 26%–30% YoY) and FY revenue of $2.335–$2.355 billion (up ~58%–59% YoY) while Zacks consensus EPS sits at $0.04 for Q4 and $0.48 for the year. The quarter showed increasing subscribers and monthly online revenue per average subscriber but simultaneous margin contraction and a “dismal” bottom line, which directly pressured the share price and investor sentiment.

The company faces pronounced operational and regulatory risks as it scales into sterile compounding, peptide manufacturing and laboratory testing, increasing inspection and compliance cost exposure, and uncertainty over the permissibility of compounded GLP-1 therapies could disrupt an important weight‑loss revenue stream. Rapid expansion, intensified competition from larger incumbents and the need to preserve brand trust across sensitive categories (testosterone, menopause, mental health) create execution risk that has driven a 20% downward revision to 2025 EPS estimates and a Zacks Rank of #4 (Sell).

Offensive catalysts include the Labs testing launch, category expansions (menopause, hormone care), the ZAVA acquisition and planned Canada entry plus AI investments, yet valuation is mixed: forward 12‑month P/S of 2.9x is below the industry 5.1x average but above the three‑year median of 2.5x, implying upside is conditional on margin recovery and regulatory control.

Key Decisions for Investors

• Avoid initiating new full-scale long positions until HIMS demonstrates sequential margin improvement and clearer regulatory outcomes for compounding and GLP-1 offerings
• Monitor near-term readouts for Labs adoption metrics, any state or federal enforcement actions in sterile compounding, and quarterly margin guidance versus the $605–$625M Q4 revenue band as primary triggers for reassessing conviction
• Consider conservative allocation or hedge strategies (e.g., collars or buying puts) if retaining exposure given significant execution risk despite attractive forward P/S versus peers
• Watch analyst estimate revisions and the company’s ability to translate ZAVA and international expansion into repeatable, margin-accretive revenue before increasing exposure